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related risk increasing line-
arly with mean whole heart
dose. This study aimed to
validate these findings and
assesses additional risk fac-
tors for radiation-related
myocardial infarction in a
case-control study nested
within a cohort of BC survi-
vors treated 70 years of age
during 1970-2009. The study
confirms a linear relationship
between mean whole heart
dose and myocardial infarc-
tion risk after radiation for
breast cancer.Methods and Materials: A nested case-control study was conducted within a cohort of
BC survivors treated during 1970 to 2009. Cases were 183 patients with MI as their
first heart disease after BC. One control per case was selected and matched on age
and BC diagnosis date. Information on treatment and cardiovascular risk factors
was abstracted from medical and radiation charts. Cardiac doses were estimated for
each woman by reconstructing her regimen using modern 3-dimensional computed to-
mography planning on a typical patient computed tomography scan.
Results: Median age at BC of cases and controls was 50.2 years (interquartile range,
45.7-54.7). Median time to MI was 13.6 years (interquartile range, 9.9-18.1). Median
MWHD was 8.9 Gy (range, 0.3-35.2 Gy). MI rate increased linearly with increasing
MWHD (excess rate ratio [ERR] per Gy, 6.4%; 95% confidence interval, 1.3%-
16.0%). Patients receiving 20 Gy MWHD had a 3.4-fold (95% confidence interval,
1.5-7.6) higher MI rate than unirradiated patients. ERRs were higher for younger
women, with borderline significance (ERR<45years, 24.2%/Gy; ERR50years, 2.5%/
Gy; Pinteraction Z .054). Whole heart dose-volume parameters did not modify the
dose-response relationship significantly.
Conclusions: MI rate after radiation for BC increases linearly with MWHD. Reduc-
tions in MWHD are expected to contribute to better cardiovascular health of BC
survivors. 2019 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Survival in women with breast cancer (BC) has improved
substantially in recent decades as a result of more effective
treatments and earlier diagnoses.1-5 However, radiation
therapy, anthracycline-based chemotherapy, and targeted
therapies can cause heart disease.6-8 In the case of radiation
therapy, cardiac exposure is associated with an increased
risk of ischemic heart disease (IHD).9-11 This may occur
through injury to the small vessels in the heart muscle
(microvascular damage) or through atherosclerosis of the
larger blood vessels (macrovascular damage).12,13
The risk of IHD appears to increase linearly with
increasing mean whole heart radiation dose (MWHD).14,15
In a large case-control study of women irradiated for BC,
the rate of major coronary events increased by 7.4%/Gy
MWHD.14 The increase started within 5 years of exposure,
sooner than previously anticipated.16,17 It was also found
that the percentage increase in IHD per Gy was similar in
women with and without cardiovascular risk factors, sug-
gesting that the absolute radiation-related increase is higher
in those with preexisting cardiovascular risk factors. These
associations require further study in younger women (ie,
<50 years) diagnosed with BC.
Substantial progress has been made in reducing cardiac
radiation doses in BC radiotherapy.18-20 Nevertheless, some
recent regimens used to irradiate the left internal mammary
nodes still may expose the heart toz8 Gy.21 Quantification
of the effect of radiation on the heart may help to predict
IHD risk for women being considered for BC radiation
therapy today. It may also help to identify BC survivors
who may benefit from cardiac surveillance.
This study aimed to examine the radiation dose-response
relationship for myocardial infarction (MI) in a populationof younger BC patients (median age 50 years at BC diag-
nosis). It also investigates the effects of different whole
heart dose-volume radiation measures and cardiovascular
risk factors on the dose-response relationship.Methods
Cohort population
A nested case-control study of MI after BC was conducted
within a cohort of long-term BC survivors treated in the
Netherlands between 1970 and 2009. The cohort was
identified through hospital-based registries at the
Netherlands Cancer Institute, Amsterdam and Erasmus
MC-Cancer Institute, Rotterdam, the Netherlands. Female
patients were included in the cohort if they had histologi-
cally confirmed, stage I to III invasive BC or ductal carci-
noma in situ and were diagnosed before the age of 71 years.
Details of the data collection procedures have been pub-
lished previously10,22 and are outlined in Methods E1
(available online at https://doi.org/10.1016/j.ijrobp.2018.
10.025). In brief, for patients in the cohort, information
on BC recurrence, distant metastases, second cancer inci-
dence, cardiovascular disease incidence, cardiovascular risk
factors, and causes of death was obtained through regis-
tries, medical files, general practitioners, and cardiologists.
Case-control study
MI diagnoses in the cohort were ascertained from medical
files and through questionnaires sent to the general practi-
tioner. In the Netherlands, all residents are expected to have
a general practitioner. Medical correspondence from
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records are preserved by the general practitioner throughout
a patient’s life and for at least 15 years after a patient’s
death. When the treating cardiologist was known and event
information obtained from the general practitioner/medical
file was unclear, an additional questionnaire was sent to the
cardiologist to confirm the MI diagnosis. Patients with MI
after BC were eligible as cases if they met the following
criteria: (1) BC was the first invasive malignancy (ignoring
nonmelanoma skin cancer); (2) they were free from BC
recurrence, distant metastases, second cancer, heart failure,
and valvular heart disease when diagnosed with MI. Heart
failure and valvular heart disease were addressed in sepa-
rate case-control studies. A rhythm disorder or angina
pectoris before MI was not an exclusion criterion. In total
183 patients with a diagnosis of MI after BC were selected
as cases.
For each MI case, one control was selected from the
cohort, matched on age at BC diagnosis (5 years) and
date of BC diagnosis (5 years). Only patients for whom
we could collect information on cardiovascular disease
were considered as potential controls. Controls had to be
alive and free from BC recurrence, distant metastases,
second cancer, MI, heart failure, and valvular heart disease
until the cutoff date, which was defined as the date of BC
diagnosis plus a time interval equal to the time between BC
diagnosis and MI diagnosis for the paired case. Cases were
permitted to be controls up to the date when they developed
MI, and controls were selected with replacement. In total,
183 controls (178 unique individuals) were matched to the
cases. Four controls later became a case.
Data collection
Data at BC diagnosis regarding medical history (including
prior cardiovascular diseases, diabetes, and hypertension),
smoking history, and body mass index (BMI) were
abstracted from medical files. Hypertension was coded as
present if a patient was on medication for hypertension or if
a diagnosis of hypertension was given in the medical re-
cord. Information on cardiovascular risk factors diagnosed
after BC diagnosis was also collected. Treatment informa-
tion, including surgery, chemotherapy regimen, and endo-
crine therapy, was abstracted. Copies of radiation charts for
individual patients were obtained for patients who received
radiation therapy. Information on target definition, field
borders, total dose, dose per fraction, beam energy, and the
use of shielding, wedges, and bolus was obtained from the
charts.
Radiation therapy dosimetry
A ‘typical computed tomography (CT) scan’ was used to
estimate cardiac doses retrospectively for each woman in
the study (Methods E2; available online at https://doi.org/
10.1016/j.ijrobp.2018.10.025). Radiation therapy chartswere available for 314 of the 316 individual irradiated
women in the study. Fifty-two regimens were identified and
reconstructed on the typical CT scan (Table E1; available
online at https://doi.org/10.1016/j.ijrobp.2018.10.025).
Dose distributions were generated for cobalt, electron, and
megavoltage beams using modern 3-dimensional CT
treatment planning (Varian EclipseTM Treatment Planning
System Version 10.0.39, Varian Medical Systems, Palo
Alto, CA). Dose distributions from orthovoltage fields were
generated using manual planning. Typical MWHD, mean
left ventricle dose, and the percentage volume of the heart
receiving 5, 10, 15, 20, 25, 30, 35, and 40 Gy (V5-V40)
were estimated using dose-volume histograms. Doses were
estimated for each individual woman using the total dose
(100%) received as recorded in individual radiation therapy
charts and the dose-volume histogram of the regimen
received.Statistical analysis
Rate ratios (RRs) for MI for different levels of each factor
were calculated using logistic regression conditioning on
strata. Strata were defined by the matching variables age at
BC diagnosis (10-year categories), year of BC diagnosis
(10-year categories), and follow-up duration (5-year cate-
gories). One individual, who appeared as a control twice
within the same stratum, was included only once in the
analysis.
Confidence intervals (CIs) were estimated using the
Wald method for factors with 2 levels. For factors with
more than 2 levels, Wald method CIs were used to derive
CIs for each category, including the reference category,
from the amount of information in that category.23 Multi-
variable regression was used to assess and control for po-
tential confounders. A factor was considered a potential
confounder if the RR after adjustment for the factor
changed by 10% or more.
The excess rate ratio (ERR) of MI associated with a
one Gy increase in radiation exposure (ie, the proportional
increase in MI rate per unit increase in dose) was estimated
using a linear odds model conditional on strata defined by
the matching variables. The model for the MI rate was
Km(1 þ bd) where d is MWHD for each woman, Km is the
MI rate at zero MWHD in the mth stratum, and b is the
ERR. Nonlinearity was tested by adding an exponential
term: Km(1 þ bd*exp[dd]). The significance of the dose-
response relationship was evaluated using the likelihood
ratio test. Interactions were evaluated by including inter-
action terms as categorical or continuous variables.
Approximate cumulative MI risks and 95% CIs were
estimated from the treatment-specific RRs together with the
cumulative MI risk for the entire cohort. Death from any
cause other than MI or sudden cardiac death was treated as
a competing risk. Overall survival rates after a diagnosis of
MI were estimated using the Kaplan-Meier method with
cases censored at either last known follow-up date or date
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Software version 13.0 (StataCorp LP, College Station, TX)
and Epicure version 1.8 (Hirosoft International, Eureka,
CA).
Results
Patient characteristics
The median age of cases at BC diagnosis was 50.2 years
(interquartile range [IQR], 45.8-54.7; Table 1). Median
time between BC diagnosis and MI diagnosis was
13.6 years (IQR, 10.3-18.2). Left-sided BC was more
common than right-sided BC in cases and controls (53.6%
and 55.5% left-sided vs 46.4% and 44.5% right-sided,
respectively) and 57.9% of cases and 58.8% of controls
had node-negative disease at BC diagnosis; these differ-
ences were not statistically significant (Table 1). Five year
and 15-year cumulative survival among cases were 85%
and 56%, respectively (Fig. E1; available online at https://
doi.org/10.1016/j.ijrobp.2018.10.025). Twenty-three pa-
tients (13%) died on the day of MI diagnosis.
Treatment-related risk factors
Surgery, endocrine therapy, and chemotherapy (with or
without anthracyclines) were not associated with a signifi-
cantly increased MI rate (RR mastectomy vs breast-
conserving surgery, 1.04 [95% CI, 0.58-1.86]; RR
hormone therapy vs not, 0.71 [95% CI, 0.29-1.75]; RR non-
anthracycline chemotherapy vs no chemotherapy, 0.59
[95% CI, 0.33-1.07], and RR anthracyclines vs no
chemotherapy, 1.04 [95% CI, 0.41-2.63]; Table 2). Internal
mammary chain (IMC) irradiation was associated with a
2.45-fold increased MI rate (95% CI, 1.97-3.05). Median
MWHD was 8.9 Gy (IQR, 4.8-15.0) for cases and 8.5 Gy
(IQR, 4.3-12.2) for controls (Table 2). Heart dose estimates
were highest for patients who received radiation to the IMC
only or IMC combined with breast or chest wall irradiation
(mean MWHD for right-sided breast þ IMC, chest
wall þ IMC, and IMC only were 14.5, 10.7, 9.1 Gy,
respectively; mean MWHD for left-sided breast þ IMC,
chest wall þ IMC, and IMC only were 18.6, 16.3, 14.2 Gy,
respectively) (Table E2; available online at https://doi.org/
10.1016/j.ijrobp.2018.10.025). MI rate increased with
increasing MWHD (P trend, .011), and there was a 3.4-fold
(95% CI, 1.54-7.62) increased rate for patients who
received a MWHD 20 Gy compared with patients who
received no radiation therapy (Table 2). Neither the use of
chemotherapy nor the presence of cardiovascular risk fac-
tors significantly confounded the association between
MWHD and MI rate (Table E3; available online at https://
doi.org/10.1016/j.ijrobp.2018.10.025). When we restricted
the analysis to irradiated cases and controls, similar rate
increases for the different radiation dose categories were
found (Table E4; available online at https://doi.org/10.1016/j.ijrobp.2018.10.025). Approximate 20-year cumula-
tive risks were 0.9% (95% CI, 0.5-2.0), 1.8% (95% CI,
0.9-2.6), 2.1% (95% CI, 1.6-2.6), 2.5% (95% CI, 1.9-3.2),
and 4.2% (95% CI, 1.2-7.2) for no radiation therapy
and MWHD categories <2 Gy, 2 to 9 Gy, 10 to 19 Gy, and
20 Gy, respectively (Fig. 1).
Cardiovascular risk factors
Hypertension and a BMI 30, recorded at BC diagnosis,
were the only individual patient-related cardiovascular risk
factors significantly associated with an increased MI rate
(Table E5; available online at https://doi.org/10.1016/j.
ijrobp.2018.10.025). However, the presence of at least 1
cardiovascular risk factor (angina pectoris, chronic
obstructive pulmonary disease, diabetes, hypertension,
smoking, BMI 30) at BC diagnosis was associated with
an RR of 1.70 (95% CI, 1.13-2.55) compared with no
cardiovascular risk factors. When cardiovascular risk fac-
tors ever diagnosed (ie, during follow-up as well as at BC
diagnosis) were taken into account, MI rate was higher
(RR, 1.86; 95% CI, 1.19-2.90) (Table E5; available online
at https://doi.org/10.1016/j.ijrobp.2018.10.025).
Radiation dose-response relationship
A linear dose-response relationship between MWHD and
MI rate was found. The ERR for MI increased by 6.4%/Gy
(95% CI, 1.3%-16.0%; Fig. 2). A model that allowed for
curvature gave no significant improvement in fit. When
considering potential modifiers of the effect of MWHD on
MI rate (Table 3), we found that ERRs were highest in
women aged <45 years at BC diagnosis (24.2%/Gy; 95%
CI, 4.4%-82.3%) and tended to decrease with older age
(ERR50-70years, 2.5%/Gy; 95% CI, 1.4% to 11.9%)
(Pinteraction based on trend test, .07; Pinteraction based on test
for homogeneity between ERR<45years and ERR50-70years,
.054). ERRs increased with longer follow-up (Pinteraction
based on trend test, .25; Pinteraction based on test for ho-
mogeneity between ERR<10years and ERR15years, 0.053).
The dose-response relationship for women with and
without cardiovascular risk factors at BC diagnosis was
similar (Pinteraction > .50). Also, when considering cardio-
vascular risk factors ever diagnosed, results did not change.
Whole heart dose-volume parameters
MWHD, mean left ventricle dose, and whole heart dose-
volume measures were highly correlated (Pearson correla-
tion coefficients ranged from 0.69 to 0.96). No other
confounders of the relationship between V5 to V40 and MI
rate were identified. In univariable models, MI rates were
significantly increased when 30% of the heart received 5
to 30 Gy (RRs, 1.97-2.86; Table 4). The addition of
MWHD as a continuous parameter to the separate dose-
volume models did not significantly improve the fit of the
Table 1 Characteristics of myocardial infarction cases and matched controls
Total
Cases Controls
Pz183 (N) 100 (%)* 182y (N) 100 (%)*
Age at breast cancer diagnosisx
Median age (IQR) in years 50.2 45.8-54.7 50.2 45.5-54.6
<40 (22-39) y 9 4.9 10 5.5
40-49 y 78 42.6 78 42.9
50-59 y 77 42.1 75 41.2
60 (60-70) y 19 10.4 19 10.4
Year of breast cancer diagnosisx
1970-1979 41 22.4 41 22.5
1980-1989 95 51.9 92 55.6
1990-1999 29 15.9 34 18.7
2000-2009 18 9.8 15 8.2
Time to MI/cutoff datex,{
Median time (IQR) in years 13.6 10.3-18.2 13.7 10.3-18.2
<5 (1-4) y 13 7.1 13 7.1
5-9 y 31 16.9 31 17.0
10-14 y 60 32.8 59 32.4
15-19 y 48 26.2 48 26.4
20 (20-29) y 31 16.9 31 17.0
Age at MI diagnosis/cutoff date{
Median age (IQR) in years 64.2 58.5-70.2 63.9 58.5-70.2
<50 (40-49) y 7 3.8 8 4.4
50-59 y 51 27.9 50 27.5
60-69 y 74 40.4 74 40.7
70-79 y 45 24.6 44 24.2
80 (83-89) y 6 3.3 6 3.3
Laterality of breast cancer
Right 85 46.4 81 44.5
Left 98 53.6 101 55.5 .72
Nodal status
Negative 106 57.9 107 58.8
Positive 75 41.0 74 40.7
Unknown 2 1.1 1 0.5 .91
Tumor size*
<2 cm 58 31.7 76 41.8
2-5 cm 88 48.1 72 39.6
5 cm 6 3.3 10 5.5
Unknown 31 16.9 24 13.2 .09
Abbreviations: BC Z breast cancer; IQR Z interquartile range; MI Z myocardial infarction.
* Percentages may not total 100 because of rounding.
y Cases and controls were selected with replacement. When an individual appeared as a control twice within the same stratum, it was included only
once in the analysis (n Z 1).
z P value for difference between tumor characteristics of cases and controls, calculated within strata (defined by matching variables) and excluding the
unknown category.
x Matching variables.
{ Derived from matching factors. Cutoff date for controls was defined as the date of BC diagnosis plus a time interval equal to the time between BC
diagnosis and MI diagnosis for the paired case.
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was a better predictor than MWHD for the development of
MI (ie, the deviance of ERR models was similar or worse
when the dose-volume parameters were used to predict MI
instead of the MWHD). Also, the addition of V5 to V40 to
the linear odds model for MWHD did not significantly
improve the fit of the ERR model (data not shown). No
evidence for effect modification by any of the dose-volume
parameters V5 to V40 was found (data not shown).Discussion
In this study we found that MI rate increases linearly by
6.4% per Gy increase in MWHD in BC survivors with a
median age of 50 years at BC diagnosis and that there was a
3.4-fold increased MI rate at a MWHD of 20 Gy. We did
not find any evidence that the percentage increase in
MWHD rate per Gy differed by presence or absence of
Table 2 Associations between treatment characteristics and rate of myocardial infarction
Total
Cases Controls
Rate ratio* 95% CI Py183 (N) 100 (%)z 182 (N) 100 (%)z
Treatment model
Surgery
Breast conserving surgery (BCS) 82 44.8 87 47.8 1.00x -
Mastectomy 101 55.2 95 52.2 1.04 0.58-1.86 .90
Endocrine therapy
No 167 91.3 166 91.2 1.00x -
Yes 16 8.7 16 8.8 0.71 0.29-1.75 .46
Chemotherapy (CT)
No 140 76.5 132 72.5 1.00x 0.89-1.12
CT, no anthracyclines 29 15.9 36 19.8 0.59 0.33-1.07
Anthracycline-based CT 14 7.7 14 7.7 1.04 0.41-2.63 .23
Radiation therapy (RT)
No 16 8.7 27 14.8 1.00z 0.50-1.99
RT, no IMC 51 27.9 65 35.7 1.20 0.67-2.18
RT, IMC 116 63.4 90 49.5 2.45 1.97-3.05 .006
Mean whole heart dose (MWHD)k
Median MWHD (IQR) in Gy 8.9 4.8-15.0 8.5 4.3-12.2
No RT 16 8.8 27 15.0 1.00x 0.52-1.91
<2 Gy (mean 1 Gy) 29 15.9 34 18.9 1.44 0.84-2.48
2-9 Gy (mean 7 Gy) 62 34.1 62 34.4 1.72 1.23-2.42
10-19 Gy (mean 14 Gy) 57 31.3 48 26.7 2.06 1.40-3.02
20 Gy (mean 26 Gy) 18 9.9 9 5.0 3.42 1.54-7.62 .011{
Abbreviations: CI Z confidence interval; IMC Z internal mammary chain; IQR Z interquartile range; MI Z myocardial infarction.
* Univariable rate ratios for MI for different levels of each factor were calculated using logistic regression conditioning on strata defined by the
matching variables.
y P value for difference between treatment characteristics of cases and controls, calculated within strata (defined by matching variables).
z Percentages may not total 100 because of rounding.
x Reference category.
k This model includes 362 patients. Three patients were dropped; for one irradiated case and one irradiated control, dosimetry was not performed. One
control was dropped because it was the only patient left in the stratum.
{ P for trend across categories.
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are consistent with the previously published radiation dose-
response relationship between MWHD and MI rate in BC
survivors, which found an MI rate of 7.4% per Gy increase
in MWHD for women both with and without cardiovascular
risk factors at time of radiotherapy.14 Moreover, similar
results were reported in a study assessing the dose-response
relationship for MWHD and the risk of IHD in Hodgkin
lymphoma (HL) survivors.15
Our results suggest that ERR per Gy was higher for the
youngest women (aged <45 years at BC diagnosis) and this
effect had borderline significance (Pinteraction Z .054). It is
notable that Van Nimwegen et al15 also found ERRs to be
highest in patients treated for HL at the youngest ages.
However, ERRs for HL patients treated at an age compa-
rable to our youngest age group were lower than we iden-
tified (ie, 4.2%/Gy in HL patients irradiated between ages
36 and 50 vs 24.2%/Gy in our patients irradiated at
<45 years, median 37 years).15 In a case-control study by
Darby et al,14 no significant effect of age was found on the
slope of the dose-response relationship between MWHDand major coronary event rate. Some cohort studies in HL
survivors and BC survivors have, however, reported that
younger age is associated with higher relative risks of
radiation-induced heart disease.24 Whether radiation ther-
apy is associated with larger percentage increases in the MI
rate per Gy MWHD in very young BC patients (ie, treated
before age 40 years) remains an important gap in knowl-
edge and requires further investigation.
In some earlier studies it was found that radiation ther-
apy was not associated with IHD during the first 10 years
after exposure,16,17 but evidence is now emerging that ra-
diation therapy can lead to increased IHD rates within the
first 5 years.14,25 We, however, did not identify increased
MI rates within the first 10 years after BC diagnosis
(ERR<10years, 0.1%; 95% CI, 2.9% to 9.5%). This could
be due to the inclusion of relatively young women in our
study; almost 90% of our patients were aged <60 years at
BC diagnosis. In contrast, in the study by Darby et al14
almost half of included women were aged 60 years at
BC diagnosis. In another study, presenting increased rates
of major acute coronary events in relation to MHD within
RR linear
ERR: 6.4%/Gy (95% CI: 1.3-16.0, p=0.006)
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Fig. 2. Dose-response relationship between rate of
myocardial infarction and mean whole heart dose. The
regression line is the best fitting linear dose response
relationship (RR Z k[1.18 þ 0.06389*MWHD];
P Z .006). This results in an ERR of 6.4%/Gy (95% CI,
1.3-16.0). Squares indicate point estimates for dose cate-
gories (no RT, <2 Gy, 2-9 Gy, 10-19 Gy, 20 Gy; Table 2)
and are plotted at the mean MWHD of each dose category.
No significant departure from linearity was identified. The
sum of the squared distances between the point estimates
for dose categories was used to find the best fit of the linear
dose-response to the categorical estimates, resulting in a
linear RR of 1.18 at 0 Gy. Abbreviations: CIZ confidence
interval; ERRZ excess rate ratio; MWHDZ mean whole
heart dose; RR Z rate ratio; RT Z radiation therapy.
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Fig. 1. Modeled cumulative myocardial infarction risk
for cases by categories of mean whole heart dose. Cumu-
lative risks of myocardial infarction (MI) as a first cardiac
event among women diagnosed with breast cancer (BC)
when aged 70 years (median age at BC diagnosis,
50.2 years (interquartile ratio [IQR], 45.8-54.7) and median
age at MI diagnosis, 64.1 years (IQR, 58.5-70.2)) by time
since initial BC treatment for categories of mean whole
heart dose. Cumulative risks were calculated from the MI
rate ratios for different dose categories (Table 2) and the
cumulative MI risk for the entire BC cohort in which this
study is embedded, with death as a competing event.
Abbreviation: RT Z radiation therapy.
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women was also higher (59 years; range, 26-84 years)
compared with the median age of our study population.25
Strong conclusions about the presence of latency in the
development of radiation-induced IHD, however, cannot be
drawn from our data because follow-up time was not a
significant effect modifier and the number of included cases
is rather small to assess the effects in different follow-up
groups.
We found that none of the whole heart dose-volume
parameters was a better predictor than MWHD for the
development of MI and we found no evidence for effect
modification of the dose-response relationship by any of the
dose-volume measures. In a recent study among women
treated during 2005 to 2008 for BC or ductal carcinoma in
situ, the left ventricle V5 (LV-V5) seemed to be a better
predictor of acute coronary events than MWHD.25 An
important limitation of that study is, however, that there
were only 30 patients who developed an event, whereas we
included 183 cases of MI after BC radiation therapy. The
women included in the 2 studies were also irradiated in
different eras, 1970s to 2000s in our study and 2005 to 2008
in the other study, so radiation techniques and the distri-
bution of MWHD are different. Hence we cannot compare
our findings directly.
More information is needed on whether, for a given
MWHD, the dose-response relationship differs in situations
in which the heart is partly irradiated (“a lot to a little”)
versus situations in which the heart is homogeneously
irradiated (“a little to a lot”).26 Our data, however, do notallow us to study whether, for a given MWHD, dose in-
homogeneity across the heart is a significant predictor of
MI. Variation in the dose-volume measures was limited
given that most women received a high dose to a small part
of the heart (“a lot to a little”) and MWHD and our dose-
volume measures were strongly correlated. Furthermore
the number of cases in each dose-volume category was too
low to draw conclusions around the effects of exposing
varying proportions of the heart to a certain radiation dose.
Schneider et al26 investigated this topic by modeling the
dose-response relationship using relative seriality models to
extrapolate to situations in which no data are currently
available. They suggested that the dose-response relation-
ship may be sigmoidal rather than linear when the heart is
homogeneously irradiated (“a little to a lot”). In a recent
paper by Hahn et al,27 among HL survivors it was also
found that increasing dose inhomogeneity was a significant
Table 3 Excess rate ratios of myocardial infarction per Gy mean whole heart dose for subgroups
Cases (N) Controls (N) ERR (%) 95% CI P
All patients 183 182 6.4 1.3-16.0 0.006*
Age at BC diagnosis
<45 y 40 41 24.2 4.4-82.3
45-49 y 47 47 11.1 1.2-40.1
50-70 y 96 94 2.5 1.4 to 11.9 .07y
Year of BC diagnosis
1970-1979 41 41 4.0 3.0 to 30.2
1980-1989 95 92 8.0 0.8-26.2
1990-1999 29 34 10.5 0.0-40.8
2000 18 15 -1.6 5.1 to 21.9 >.50y
Time to MI/cutoff date
<10 y 44 44 -0.1 2.9 to 9.5
10-14 y 60 59 7.2 0.8 to 32.3
15 y 79 79 15.1 2.9-49.3 .25y
Chemotherapy (CT)
No 140 132 9.9 2.4-25.5
CT, no anthracyclines 29 36 1.5 2.4 to 24.6
Anthracycline-based CT 14 14 9.0 4.2 to 113 >.50z
Cardiovascular risk factors at BC diagnosis
No 77 101 5.1 0.3 to 17.3
Yes 106 81 7.6 0.1-27.6 >.50z
Cardiovascular risk factors ever diagnosed
No 51 75 3.9 1.6 to 18.7
Yes 132 107 7.3 0.9-22.0 >.50z
Smoking
Never smoked 96 106 6.8 0.4-21.0
Ever smoked 87 76 5.4 0.7 to 21.5 >.50z
Abbreviations: BC Z breast cancer; CI Z confidence interval; ERR Z excess rate ratio; MI Z myocardial infarction.
* P for test of ERR Z 0.
y P for interaction based on trend test with time/age as a continuous variable.
z P for interaction based on test for homogeneity across categories.
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Studies including women irradiated with CT-based radia-
tion therapy planning and women who received intensity
modulated radiation therapy will further enable investiga-
tion of the role of dose-volume parameters in relation to the
development of IHD among BC survivors.
A limitation of our study was that we were unable to use
dosimetry data derived from CT-planning scans of the pa-
tients themselves because most women were treated before
the era of CT planning. Instead, individual radiation ther-
apy regimens for irradiated patients were reconstructed on
the CT scan of a typical patient and thus the cardiac doses
may differ from presented estimates, principally because of
variation in anatomy (Methods E1; available online at
10.1016/j.ijrobp.2018.10.025). The magnitude of these
differences will be similar for cases and controls, but it will
differ between different regimens. The nature of this error,
known as a Berkson error, has been found to cause no bias
in the resulting dose-response relationship.28 Furthermore,
it should be noted that cumulative MI risks by dose cate-
gories were estimated based on the cumulative MI risk
identified in our BC cohort. Over the past decade, decreases
in MI rate have been reported in the general population.Because the cumulative absolute risk is affected by the
background MI rate, the cumulative incidence for future
BC patients is likely to be lower than presented here.
An important strength is that this large case-control
study is nested within a well-characterized cohort for which
comprehensive oncologic and cardiovascular follow-up
information was available. We ascertained MI diagnosis
through the patients’ GP, who in the Netherlands routinely
receives medical correspondence from attending physicians
or the treating cardiologist. Furthermore, individual patient
dosimetry was performed and we found no evidence for
selection of irradiated patients according to health status,
because our sensitivity analyses restricted to irradiated
patients indicated similar risk estimates for categories of
MWHD.Conclusions
We found a linear dose-response relationship between
MWHD and MI rate in a population of younger BC patients
(median age of 50 years at BC diagnosis), suggesting that
there is no apparent threshold dose below which MI rate is
Table 4 Associations between percentage of heart volume receiving 5-40 Gy and rate of myocardial infarction
Percentage of heart
volume receiving
5-40 Gy (V5-V40)
Median value (IQR)
Cases Controls
Rate ratio* 95% CIy PzTotalx 170 (N) 100 (%)k 169 (N) 100 (%)k
V5 40.2 (11.1-87.6)
<10% 44 25.9 62 36.7 1.00{ 0.68-1.47 -
10%-29% 29 17.1 35 20.7 1.20 0.73-1.99 .57
30% 97 57.1 72 42.6 2.02 1.43-2.85 .008
V10 37.1 (8.8-60.7)
<10% 63 37.1 88 52.1 1.00{ 0.70-1.43 -
10%-29% 21 12.4 15 8.9 1.96 0.99-3.87 .09
30% 86 50.6 66 39.1 1.97 1.40-2.78 .007
V15 29.3 (8.0-40.5)
<10% 64 37.7 91 53.8 1.00{ 0.72-1.39 -
10%-29% 22 12.9 15 8.9 2.01 1.03-3.93 .07
30% 84 49.4 63 37.3 2.05 1.41-2.98 .005
V20 17.1 (7.4-36.5)
<10% 73 42.9 97 57.4 1.00{ 0.71-1.41 -
10%-29% 34 20.0 33 19.5 1.42 0.87-2.30 .25
30% 63 37.1 39 23.1 2.28 1.53-3.41 .002
V25 10.7 (6.8-19.1)
<10% 77 45.3 104 61.5 1.00{ 0.73-1.37 -
10%-29% 53 31.2 46 27.2 1.60 1.04-2.45 .08
30% 40 23.5 19 11.2 2.86 1.67-4.90 .001
V30 6.6 (4.4-11.4)
<10% 119 70.0 140 82.8 1.00{ 0.78-1.29 -
10%-29% 25 14.7 14 8.3 2.15 1.11-4.13 .033
30% 26 15.3 15 8.9 2.12 1.12-4.01 .033
V35 3.0 (1.2-6.2)
<10% 132 77.7 149 88.2 1.00{ 0.76-1.31 -
10%-29% 24 14.1 12 7.1 2.32 1.17-4.58 .025
30% 14 8.2 8 4.7 2.11 0.89-5.03 .11
V40 0.3 (0-5.4)
<10% 143 84.1 154 91.1 1.00{ 0.88-1.13 -
10%-29% 23 13.5 14 8.3 1.77 0.88-3.57 .12
30% 4 2.4 1 0.6 5.29 0.57-49.4 .15
Abbreviations: CI Z confidence interval; IQR Z interquartile range; MI Z myocardial infarction.
* Univariable rate ratios for MI for different levels of each factor were calculated using logistic regression conditioning on strata defined by the
matching variables.
y Wald method CIs were used to derive CIs for each category, including the reference category.
z P value for difference of dose-volume categories of cases and controls, calculated within strata (defined by matching variables), with <10% as a fixed
reference group.
x This model includes 339 patients. Twenty-six patients were dropped: for one irradiated case and one irradiated control, dosimetry was not performed.
For 22 patients (11 cases and 11 controls) it was not possible to estimate dose-volume parameters study because they had a combination of orthovoltage
and electron/megavoltage treatment (manual planning). One case and one control were additionally dropped because they were the only patient left in the
stratum.
k Percentages may not total 100 because of rounding.
{ Reference category.
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mally reducing MWHD using modern radiation techniques
to optimize the cardiovascular health of BC survivors.References
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